Erwin A. Kruger, M.D.

  1. Hand Surgeon
  2. Plastic Surgeon

Publications

  1. Hammond JB, Teven CM, Flug JA, Jokerst CE, Howarth AL, Shrout MA, Laitinen MA, Foley BM, Kruger EA, Casey WJ 3rd, Rebecca AM. The Chimeric Gracilis and Profunda Artery Perforator Flap: Characterizing This Novel Flap Configuration with Angiography and a Cadaveric Model. J Reconstr Microsurg. 2021 Sep; 37 (7):617-621 Epub 2021 Feb 16
    View PubMed
  2. Hammond JB, Thomas O, Jogerst K, Kosiorek HE, Rebecca AM, Cronin PA, Casey WJ 3rd, Kruger EA, Pockaj BA, Teven CM. Same-day Discharge Is Safe and Effective After Implant-Based Breast Reconstruction. Ann Plast Surg. 2021 Aug 1; 87 (2):144-149
    View PubMed
  3. Morris BE, Thornburg DA, Teven CM, Kruger EA. Surgical Management of Chronic Encapsulated Abdominal Wall Seroma 8 Years after Abdominoplasty. Plast Reconstr Surg Glob Open. 2021 Jul; 9 (7):e3697 Epub 2021 July 20
    View PubMed
  4. Hammond JB, Foley BM, James S, Rebecca AM, Teven CM, Kruger EA, Kosiorek HE, Cronin PA, Bernard RW, Pockaj BA, Casey WJ 3rd. Does Prior Breast Augmentation Affect Outcomes After Mastectomy With Reconstruction? An Analysis of Postoperative Complications and Reoperations. Ann Plast Surg. 2021 May 1; 86 (5):508-511
    View PubMed
  5. Hammond JB, Teven CM, Bernard RW, Lucas HD, Casey WJ, Siebeneck ET, Kruger EA, Rebecca AM. 3D Nipple-Areolar Tattoo: It's Technique, Outcomes, and Utilization. Aesthetic Plast Surg. 2021 Apr; 45 (2):453-458 Epub 2020 Sept 23
    View PubMed
  6. Hammond JB, Pflibsen LR, Kruger EA, Casey WJ 3rd, Noland SS, Lettieri SC, Rebecca AM, Struve SL, Teven CM. Pyoderma gangrenosum confined to the irradiated chest wall of the reconstructed breast. Clin Case Rep. 2021 Jan; 9 (1):445-449 Epub 2020 Dec 22
    View PubMed
  7. Hammond JB, Han GR, Cronin PA, Kosiorek HE, Rebecca AM, Casey WJ 3rd, Kruger EA, Teven CM, Pockaj BA. Exploring the Effect of Post-mastectomy complications on 5-year survival. Am J Surg. 2020 Dec; 220 (6):1422-1427 Epub 2020 Sept 06
    View PubMed
  8. Pflibsen LR, Lettieri SC, Kruger EA, Rebecca AM, Teven CM. Negative Pressure Wound Therapy in Malignancy: Always an Absolute Contraindication? Plast Reconstr Surg Glob Open. 2020 Aug; 8 (8):e3007 Epub 2020 Aug 14
    View PubMed
  9. Ben-Amotz O, Kruger EA, McAndrew C, Lantieri L, Bozentka D, Steinberg D, Chang B, Levin LS. Logistics in Coordinating the First Adult Transatlantic Bilateral Hand Transplant: Lessons Learned. Plast Reconstr Surg. 2018 Sep; 142 (3):730-735
    View PubMed
  10. Kruger EA, Ben-Amotz O, Mendenhall SD, Levin LS. The Chimeric Myo-Osseous Medial Femoral Condyle Flap for Tibial Nonunion: A Case Report. Eplasty. 2018; 18:e23 Epub 2018 July 10
    View PubMed
  11. Kruger EA, Pires M, Ngann Y, Sterling M, Rubayi S. Comprehensive management of pressure ulcers in spinal cord injury: current concepts and future trends. J Spinal Cord Med. 2013 Nov; 36 (6):572-85 Epub 2013 May 21
    View PubMed
  12. Pereira CT, Kruger EA, Sayer G, Kim J, Hu J, Miller TA, Rudkin GH. Mohs versus surgical excision in nonmelanoma skin cancers: does location matter? Ann Plast Surg. 2013 Apr; 70 (4):432-4
    View PubMed
  13. Kruger EA, Im DD, Bischoff DS, Pereira CT, Huang W, Rudkin GH, Yamaguchi DT, Miller TA. In vitro mineralization of human mesenchymal stem cells on three-dimensional type I collagen versus PLGA scaffolds: a comparative analysis. Plast Reconstr Surg. 2011 Jun; 127 (6):2301-11
    View PubMed
  14. Im DD, Kruger EA, Huang WR, Sayer G, Rudkin GH, Yamaguchi DT, Jarrahy R, Miller TA. Extracellular-signal-related kinase 1/2 is responsible for inhibition of osteogenesis in three-dimensional cultured MC3T3-E1 cells. Tissue Eng Part A. 2010 Nov; 16 (11):3485-94 Epub 2010 Sept 09
    View PubMed
  15. Li WW, Talcott KE, Zhai AW, Kruger EA, Li VW. The role of therapeutic angiogenesis in tissue repair and regeneration. Adv Skin Wound Care. 2005 Nov-Dec; 18 (9):491-500; quiz 501-2
    View PubMed
  16. Luzzio FA, Mayorov AV, Ng SS, Kruger EA, Figg WD. Thalidomide metabolites and analogues. 3. Synthesis and antiangiogenic activity of the teratogenic and TNFalpha-modulatory thalidomide analogue 2-(2,6-dioxopiperidine-3-yl)phthalimidine. J Med Chem. 2003 Aug 28; 46 (18):3793-9
    View PubMed
  17. Ng SS, Gutschow M, Weiss M, Hauschildt S, Teubert U, Hecker TK, Luzzio FA, Kruger EA, Eger K, Figg WD. Antiangiogenic activity of N-substituted and tetrafluorinated thalidomide analogues. Cancer Res. 2003 Jun 15; 63 (12):3189-94
    View PubMed
  18. Zogakis TG, Costouros NG, Kruger EA, Forbes S, He M, Qian M, Feldman AL, Figg WD, Alexander HR, Liu ET, Kohn EC, Libutti SK. Microarray gene expression profiling of angiogenesis inhibitors using the rat aortic ring assay. Biotechniques. 2002 Sep; 33(3):664-6, 668, 670.
    View PubMed
  19. Beliveau R, Gingras D, Kruger EA, Lamy S, Sirois P, Simard B, Sirois MG, Tranqui L, Baffert F, Beaulieu E, Dimitriadou V, Pepin MC, Courjal F, Ricard I, Poyet P, Falardeau P, Figg WD, Dupont E. The antiangiogenic agent neovastat (AE-941) inhibits vascular endothelial growth factor-mediated biological effects. Clin Cancer Res. 2002 Apr; 8 (4):1242-50
    View PubMed
  20. Price DK, Ando Y, Kruger EA, Weiss M, Figg WD. 5'-OH-thalidomide, a metabolite of thalidomide, inhibits angiogenesis. Ther Drug Monit. 2002 Feb; 24 (1):104-10
    View PubMed
  21. Figg WD, Arlen P, Gulley J, Fernandez P, Noone M, Fedenko K, Hamilton M, Parker C, Kruger EA, Pluda J, Dahut WL. A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer. Semin Oncol. 2001 Aug; 28 (4 Suppl 15):62-6
    View PubMed
  22. Molloy FM, Floeter MK, Syed NA, Sandbrink F, Culcea E, Steinberg SM, Dahut W, Pluda J, Kruger EA, Reed E, Figg WD. Thalidomide neuropathy in patients treated for metastatic prostate cancer. Muscle Nerve. 2001 Aug; 24 (8):1050-7
    View PubMed
  23. Kruger EA, Figg WD, Krüger EA. Protein binding alters the activity of suramin, carboxyamidotriazole, and UCN-01 in an ex vivo rat aortic ring angiogenesis assay. Clin Cancer Res. 2001 Jul; 7 (7):1867-72
    View PubMed
  24. Figg WD, Dahut W, Duray P, Hamilton M, Tompkins A, Steinberg SM, Jones E, Premkumar A, Linehan WM, Floeter MK, Chen CC, Dixon S, Kohler DR, Kruger EA, Gubish E, Krüger EA, Pluda JM, Reed E. A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res. 2001 Jul; 7 (7):1888-93
    View PubMed
  25. Berger AC, Alexander HR, Tang G, Wu PS, Hewitt SM, Turner E, Kruger E, Figg WD, Grove A, Kohn E, Stern D, Libutti SK. Endothelial monocyte activating polypeptide II induces endothelial cell apoptosis and may inhibit tumor angiogenesis. Microvasc Res. 2000 Jul; 60 (1):70-80
    View PubMed
  26. Berger AC, Feldman AL, Gnant MF, Kruger EA, Sim BK, Hewitt S, Figg WD, Alexander HR, Libutti SK. The angiogenesis inhibitor, endostatin, does not affect murine cutaneous wound healing. J Surg Res. 2000 Jun 1; 91(1):26-31.
    View PubMed
  27. Kruger EA, Duray PH, Tsokos MG, Venzon DJ, Libutti SK, Dixon SC, Rudek MA, Pluda J, Allegra C, Figg WD. Endostatin inhibits microvessel formation in the ex vivo rat aortic ring angiogenesis assay. Biochem Biophys Res Commun. 2000 Feb 5; 268 (1):183-91
    View PubMed
  28. Bauer KS, Cude KJ, Dixon SC, Kruger EA, Figg WD. Carboxyamido-triazole inhibits angiogenesis by blocking the calcium-mediated nitric-oxide synthase-vascular endothelial growth factor pathway. J Pharmacol Exp Ther. 2000 Jan; 292 (1):31-7
    View PubMed
  29. Kruger EA, Blagosklonny MV, Dixon SC, Figg WD. UCN-01, a protein kinase C inhibitor, inhibits endothelial cell proliferation and angiogenic hypoxic response. Invasion Metastasis. 2000; 18(4):209-18.
  30. Dixon SC, Kruger EA, Bauer KS, Figg WD. Thalidomide up-regulates prostate-specific antigen secretion from LNCaP cells. Cancer Chemother Pharmacol. 1999; 43 Suppl:S78-84
    View PubMed
PST-20471375